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Purpose: In Cuba, viral monitoring in the post-transplant period was not routinely performed. The aim of this research is
to identify the most frequent viruses that affect transplanted Cuban children, by implementing a viral follow-up during
the post-transplant period.
Methods: The study population included all Cuban pediatric patients who underwent solid organ transplantation (SOT)
between November 2009 and December 2012. A total of 34 transplanted pediatric patients of kidney (n = 11) and liver
(n = 23) were prospectively monitored during a 34-week period for viral DNAemia and DNAuria by simultaneous detection
of cytomegalovirus (CMV), Epstein-Barr virus, herpes simplex virus type 1 and 2, varicella zoster virus, human herpesvirus 6,
human adenovirus, and polyomaviruses (BKV and JCV) using quantitative real-time polymerase chain reaction (qRT-PCR).
Results: Viral genome of at least one virus was detected in 21 of 34 recipients, 18 patients excreted virus in urine while 12
presented DNAemia. CMV (41.2%) and BKV (35.3%) were the most frequent viruses detected during the follow-up. CMV
was the virus mainly associated with clinical symptoms and DNAemia. Its excretion in urine (with cut off value of 219
copies/mL) was associated with detection in plasma (p < 0.001); furthermore, CMV viruria was predictive of CMV viremia
(OR:8.4, CI:2.4-29.1, p = 0.001). There was no association between high viral load and
clinical complications, due to the prompt initiation of preemptive ganciclovir. Conclusion: This comprehensive viral
monitoring program effectively prevents the development of critical viral disease, thus urge the implementation of
qRT-PCR as routine for viral monitoring of transplanted Cuban organ recipients.
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Infections represent one of the most frequent complica-
tions among patients undergoing organ transplantation,
and among them viral infections constitute a significant
cause of morbidity and mortality after solid organ trans-
plantation (SOT). They not only induce specific diseases,* Correspondence: vkouri@ipk.sld.cu
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in any medium, provided the original work is pbut also favor the development of allograft damage, oppor-
tunistic infections, and acute rejection (Fishman and
Rubin, 1998). Although cytomegalovirus (CMV) is the
most common opportunistic pathogen seen in transplant
recipients, other viruses may also affect clinical outcome.
Among them, other herpesviruses, polyomaviruses and
adenoviruses are important (Imperiale and Major, 2007;
Rickinson and Kieff, 2007; Roizman et al., 2007; Wold and
Horwitz, 2007; Yamanishi et al., 2007).
Major advances in the management of all these viral in-
fections have been achieved because of the availability of
novel pharmaceutical agents. In addition, the establishmentOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and quantitative (qRT-PCR) monitoring of viral DNA
in blood or serum (DNAemia) has allowed optimal
management of antiviral treatment in many countries,
as it permits the identification of preclinical or early
stages of virus-related pathology (Humar and Michaels,
2006; Martin-Gandul et al., 2013).
However, the appropriate extent of viral monitoring and
the critical time window for initiating PCR-guided pre-
emptive antiviral therapy remain controversial. Recent
studies on the screening and management of viral infec-
tions have focused on CMV, and comprehensive data on
viral DNAemia and disease, including CMV and other
relevant viruses in the post-transplantation settings, such
as Epstein-Barr virus (EBV), herpes simplex virus (HSV),
human herpesvirus 6 (HHV6), human adenovirus (ADV),
and BK virus (BKV), are sparse. In addition, most previous
studies predominantly analyzed adult transplantation co-
horts (Schonberger et al., 2010).
The pediatric cohort is at high risk of developing
virus-related complications due to immunological imma-
turity and the increased alloreactivity risk that requires a
strong immunosuppressive treatment (Grimaldi et al.,
2005).Table 1 General information of the transplanted patients stud
Patients characteristics Total of patients n = 34
Donor* n(%) Live (%) 5 (14.7)
Deceased (%) 29 (85.3)
Age average average of years (range) 10.4 (1–17)
Cytomegalovirus IgG Pretransplant serology.
(n = 32)
29 (90.6)
Epstein Barr Virus IgG Pretransplant serology.
(n = 32)
29 (90.6)
Herpes Simplex Virus IgG Pretransplant serology.
(n = 32)
25 (78.1)





Antiviral prophylaxis (time) Ganciclovir/valganciclovir
Aciclovir (for two months
valganciclovir prophylaxis
Graft loss 4 (11.8) 1 (4.3)
Died 5 (14.7) 3 (13.0)
Successful transplant 25 (73.5) 19 (82.6)
Samples analyzed {serum/urine} 578 {289/289} 426** {213/213}
Abbreviation: IgG: Immunoglobulin G.
*All donors were seropositives to CMV, EBV and HSV IgG. **Five patients had an inc
follow up (only 20 samples).In 1970, Cuba initiated the transplantation program.
Currently, kidney and liver are the more common organ
transplants performed in children (Abdo Cuza 2010).
However, only serological pre-transplant screening is
carried out, whereas specific viral tests (qualitative PCR)
are requested when clinical signs and symptoms, sug-
gestive of viral disease, appear. Furthermore, neither
quantitative methods for monitoring of viral infections
nor preemptive therapy have ever been used in this
group of patients. The aim of this research is to identify
the most frequent viruses that affect Cuban transplanted
children, by implementing an appropriate viral follow-up
during the post-transplant period.
Results
As shown in Table 1, 29 out of the 34 (85.3%) transplanted
patients survived after the graft and 25 (73.5%) success-
fully completed the follow-up, with best results observed
for patients with liver transplantation (82.6%, 19/23 pa-
tients). Unfortunately, 14.7% of patients died immediately
or few days post-transplantation (average 25 days, range
8–48 days), mainly by complications directly linked to the
surgery or due to the low Karnofsky performance status at
the time of transplantation (Schag et al., 1984; Yates et al.,ied
(100%) Liver n = 23 (100%) Kidney n = 11 (100%)
4 (17.4) 1 (9.1)
19 (82.6) 10 (90.9)
9.6 (1–17) 13.3 (7–16)
19 (82.6) 10 (90.9)
20 (87.0) 9 (81.8)
17 (73.9) 8 (72.7)
23 (100) Prednisone 11 (100)
13 (56.5) Cs 7 (63.6)
11 (47.8) or Tacrolimus 2 (8.7)
MF) 21 (91.3) If Cs then was indicated MMF 7 (63.6)
3(13.0) Basiliximab 5 (45.5)
or Thimogam 4 (36.4)







omplete follow up (only 30 samples). ***Five patients had an incomplete
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with acute rejection (kidney), one with rejection as a result
of discontinuing the immunosuppressive therapy (liver),
and two with vascular thrombosis (kidney recipients).
In this cohort of Cuban pediatric recipients, viral DNA
was serially monitored for 238 days, on a weekly basis dur-
ing the first month, then every two weeks until 90 days
after transplantation and at monthly intervals, thereafter.
Viral DNA was detected in 21 of 34 patients (61.8%) and
22.7% of the screened samples (80/352). The highest posi-
tivity was found in urine samples (18 patients, 60/162
samples), compared to plasma (12 patients, 20/190 sam-
ples) (Table 2). The median time to first detection of viral
DNA following transplantation was 3 weeks (inter quartile
range [IQR]: 0–8.5 weeks). In urine, the interval was 4
(IQR: 0–10), while in plasma it was 8 (IQR: 2–12).
Liver recipients had detectable viral DNA in 65.2% (15/
23 patients) and kidney recipients in 54.5% (6/13 patients).
Most patients tested positive for CMV (14/34 patients
[41.2%]) or BKV (12/34 patients [35.3%]) (Table 2). In
contrast, the other viruses were only rarely detected
(HHV6/EBV 1/34 patients each [2.9%]; JC virus (JCV) 4/
34 patients [11.8%]; ADV 3/34 patients [8.8%]) and HSV
and Varicella Zoster Virus (VZV) were not detected in
any patient (Table 2).
Overall, the detection of viruses in plasma was less fre-
quent than in urine and CMV was significantly more
frequently detected in this compartment compared to the
others viruses (10/12 patients; odds ratio [OR]: 22.5, confi-
dence interval [CI]: 3.5-145.3, p < 0.001) (Table 2). In liver
transplant recipients five different viruses were detected in
plasma (CMV, HHV6, EBV, JCV and ADV), while in kidney
transplanted patients only 2 viruses (CMV and BKV) were
diagnosed. No significant association between immunosup-
pressive regimen and CMV detection was found (p > 0.05).Table 2 Distribution of positivity for different viruses, among
Virus Patients over all* Liv
N = 34 (%) N
Total positive Plasma Urine Total positive
Any 21 (61.8) 12 (35.3) 18 (52.9) 15 (65.2)
CMV 14 (41.2) 10 (29.4) 11 (32.4) 11 (47.8)
HHV6 1 (2.9) 1 (2.9) 0 1 (4.3)
EBV 1 (2.9) 1 (2.9) 0 1 (4.3)
HSV 0 0 0 0
VZV 0 0 0 0
BKV 12 (35.3) 2 (5.9) 12 (35.3) 8 (34.8)
JCV 4 (11.8) 1 (2.9) 3 (8.8) 2 (8.7)
ADV 3 (8.8) 1 (2.9) 2 (5.9) 1 (4.3)
*The total number of patients screened in each fluid does not always coincide with
more than one virus.
Abbreviations: CMV: Cytomegalovirus, HHV6: Human Herpes Virus 6, EBV: Epstein Ba
JCV: JC Virus, ADV: Adenoviruses.Six patients were detected with CMV in the two com-
partments, being more likely that patients having CMV
DNA detectable in urine also have CMV DNAemia (OR =
15.1, CI 4.6- 49.9, p < 0.001). Furthermore, CMV excretion
in urine was predictive of CMV viremia (OR: 8.4, CI 2.4-
29.1, p = 0.001). Despite all donors were seropositive for
CMV, EBV and HSV (Table 1), recipient seronegativity was
not associated with viral detection (data not shown).
Recent studies have been able to determine the presence
of co-infections or mixed infections among viral and non-
viral agents. In our study we found that the total of
patients with any co-infection (including viral and non-
viral) were 8 (23.5%) and 17.6% (6/34) showed viral co-
infections either in the same or in different compartments
at the same time point (concurrently). CMV-BKV was the
most common viral co-infection (3/6), and HHV6-CMV,
ADV-BKV, BKV-JCV and EBV-CMV co-infections were
also detected. One of these patients had two viral co-
infections (CMV-BKV and EBV-CMV) at different time
points during the follow up.
Viral load analysis for the different viruses in each type
of fluid
Viral load analysis was made for different viruses in each
sample type. In urine, the most common viruses de-
tected (CMV and BKV) showed lower viral load (me-
dian: 1.5 × 103, ranges 1.0 × 102 to 1.1 × 106 copies/mL and
median: 4.7 × 103, ranges 2.7 × 101 to 1.4 × 107 copies/mL,
respectively). In contrast, higher viruria load was detected
for ADV (median: 8.4 × 108 copies/mL, ranges 6.3 × 105 to
3.0 × 109 copies/mL) and JCV (median: 2.7 × 105copies/mL,
ranges 4.1 × 103 to 2.1 × 106 copies/mL); however these
viruses were detected less frequently than the others
(Table 2, Figure 1). The viral load levels, among viruses
excreted in urine, were significantly different (p < 0.001),the patient studied
er recipients Kidney recipients
= 23 (%) N = 11 (%)
Plasma Urine Total positive Plasma Urine
9 (39.1) 12 (52.2) 6 (54.5) 3 (27.3) 6 (54.5)
7 (30.4) 8 (34.8) 3 (27.3) 3 (27.3) 3 (27.3)
1 (4.3) 0 0 0 0
1 (4.3) 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 (0) 8 (34.8) 4 (36.4) 2 (18.2) 4 (36.4)
1 (4.3) 1 (4.3) 2 (18.2) 0 2 (18.2)
1 (4.3) 0 2 (18.2) 0 2 (18.2)
the total of positive patients, since one patient may have been detected with
rr Virus, HSV: Herpes Simplex Virus, VZV: Varizella Zoster Virus, BKV: BK Virus,
Figure 1 The figure displays the comparison of the median of viral load among each virus in serum (A), in urine (B), and of CMV
between serum and urine (C). In serum, differences between viral load medians could not be established because there were few viremic
patients. In urine, there were statistical differences between the detected viruses. There were also significant higher levels of CMV viral load in
urine compared to serum.
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0.003, respectively) and CMV vs. JCV (p = 0.005). Since the
detection of other viruses, different from CMV was
very rare in plasma, no statistical association could be
established.
The median viral loads of CMV between plasma and
urine were statistically different (p = 0.03). The highest
area under curve (AUC) value, 0.667, was achieved with
the CMV viral load in urine, at the cut off 219 copies/
mL, it reached a sensitivity of 85.2%, and a specificity of
50% for predicting CMV DNAemia (Figure 1).
Longitudinal analysis of viral detection in clinical samples
from transplanted patients during the follow-up
At the time of transplantation (time 0), mainly those
viruses excreted in urine were detected (CMV in two
patients, BKV and JCV in three patients each of them).
Because of the prophylaxis with ganciclovir (GCV) or val-
ganciclovir (VGV) in months 1–3 after the transplantation,
CMV was detected in only one patient. Nevertheless
around the weeks 10–14 after transplantation, CMV detec-
tion increased to five patients. In addition, BKV excretion
was detected throughout the follow-up. The median time
to initial CMV, BKV and JCV detection was 11 weeks
(IQR: 3.5-12.5), 5 weeks (IQR: 0.75-17.5) and 0 weeks
(IQR: 0–0.75) respectively, following transplantation. The
time to first detection of each virus was statistically differ-
ent for JCV vs CMV (p = 0.002) and JCV vs BKV (p =
0.004). EBV, HHV6, and ADV were less frequently found
during the longitudinal screening (<10%) and the median
time to first detection of those viruses ranged from 2 to
10 weeks after the transplantation. After the week 30, more
than 90% of patients under monitoring cleared the viruses
from the compartments analyzed.
Viral detection and clinical impact
CMV was the most frequently detected virus in patients
with symptoms and complications during the follow-up.
It was found causing direct complications in 3 patients
(CMV-syndrome, patients No 22, 23 and 15, Table 3)
who were treated with GCV or VGV. This virus was alsodetected in 4 patients who presented further complica-
tions (bacterial, rejection episode, biliary stricture) and
were treated with GCV or VGV; 3/4 were already under
treatment with antiviral prophylaxis at the moment of
the clinical complications (data not shown) and 1/4 re-
ceived therapeutic treatment (patient No 18, Table 3).
CMV was also found in patients without any symptoms
or complications (7 patients), 3 of these recipients had
viremia and received preemptive antiviral treatment
(patients No 1, 8 and 12, Table 3).
ADV excretion in urine was associated with a febrile
syndrome in one patient, which resolved spontaneously
(data not shown).
In total, 7 patients received supplementary preemptive
or therapeutic therapy with GCV or VGV, based on the
virological results obtained during the follow-up and/or
the clinical symptoms (Table 3). All treated patients
showed clinical and/or virological evidence of response
to the antiviral therapy. No association between viral-
related disease and high viral loads was observed, be-
cause of the early onset of antiviral therapy in patients
with detectable viremia (Table 3).
The median time of GCV or VGV preemptive treatment
was 13.5 weeks (IQR: 11.5-25.3 weeks). During preemptive
therapy, no toxicities, such as renal or hematologic im-
pairment, were observed.
Discussion
One of the most important factors for achieving a success-
ful transplantation in children seems to be the status of
the patients in the pre-transplant period, since it influences
in the early survival after the procedure (Herthelius et al.,
2012; Rao et al., 2011). Transplanted patients present a
higher susceptibility to the development of infections and
surgical complications; these seemed to be the main causes
of early death in the current study, because two patients
died of vascular thrombosis, another of lung hemorrhage,
other with disseminated intravascular coagulation and one
case with sepsis. The rate of transplantation success found
in the present study is similar to the rates of survival in de-
veloping countries (Rao et al., 2011; Wang et al., 2007).






Therapy Weeks of follow-up at beginning







1 Liver Valganciclovir 14 (4) asymptomatic CMV viremia: 103 No viremia
8 Liver Valganciclovir 11 (4) asymptomatic CMV viremia: 104 No viremia





23 Liver Ganciclovir +
Valganciclovir
5 (5 days + 4) Elevated AST,
ALT
Viremia: CMV 104 No viremia
Urine: CMV 103 Urine: no virus detected
12 Kidney Valganciclovir 29 (4) asymptomatic Viremia: CMV 10, BKV 10 No viremia
Urine: CMV 102, BKV 107 Urine: CMV 10, BKV 104
15 Kidney Valganciclovir 22 (4) Fever Viremia: CMV 102 No viremia
Urine: CMV 105 Urine: no virus detected
34 (12) Fever and
chronic reject
Viremia: CMV 102 No viremia
Urine: CMV 106 Urine: CMV 105
18 Kidney Valganciclovir 13 (12) Urinary
infection




Abbreviations: AST: aspartate aminotransferase, ALT: alanine aminotransferase, CMV: Cytomegalovirus, EBV: Epstein-Barr virus, BKV: BK virus.
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and mortality following transplantation. Although CMV is
the most common opportunistic pathogen seen in trans-
plant recipients, numerous other viruses have also affected
outcome. It has been shown that preventive measures
such as pre-transplant screening, prophylactic antiviral
therapy, or post-transplant viral monitoring may limit the
impact of these infections. Recent advances in laboratory
monitoring using quantitative methods and antiviral ther-
apy have further improved outcome.
In Cuba, great efforts have been undertaken in reducing
the morbidity and mortality related to the transplant,
however, so far no viral monitoring in the post-transplant
period was routinely performed and quantitative PCR
assays were not available for the screening of transplanted
patients. Thus, the present study has allowed, not only
assessing the replication of different viruses in samples
from pediatric transplanted recipients, but has also con-
tributed to the improvement in the management of their
clinical course.
Of note, 61.8% of our patients tested positive for viral
DNA at least once, similar to other reports (Schonberger
et al., 2010; Verdeguer et al., 2011). In agreement with
most of the reviewed literature, CMV represents the
most frequent virus detected in transplanted patients
(Comoli and Ginevri, 2012). Costa et al., have detected
active infection by CMV in 43.3% of liver transplant
recipients followed for one year, while HHV6 was
detected in 40% (Costa et al., 2011). The present result
is also similar to the rate found in a prospective viral
monitoring performed in German children undergoing
allogeneic hematopoietic stem cell transplantation. Theyreported an overall detection of any viral DNA in 62.5%
of the recipients, with CMV being detected in the serum
of 28% of patients while HHV6, ADV and BKV were less
frequently detected (Schonberger et al., 2010). Another
study performed in Spain, also identified CMV as the
most frequent virus (28.9%) among the plasma analyzed
(Verdeguer et al., 2011).
The introduction of molecular methods made it possible
to detect co-infections with different pathogens in kidney
transplant and allogeneic stem cell recipients (Abdo et al.,
2009; Yamamoto and Nakamura, 2000; Zawilinska et al.,
2008). Co-infections are frequently detected in immuno-
compromised patients as the altered host immune
response is unable to control latent viruses (Bissinger
et al., 2005; Pliquett et al. 2012). However, the exact impli-
cations of co-infections with regard to the pathogenesis of
transplantation-associated diseases are not well known
(Sampaio et al., 2012). In the present study, CMV was as-
sociated with viral co-infections in blood, which may be
predictable, since CMV replication is known to increase
the risk of other opportunistic infections (50). In addition,
the detection of CMV/BKV co-infection could very likely
indicate the presence of significant immunosupression.
It has been demonstrated that the detection of CMV-
DNA in plasma by qRT-PCR appears to be an effective
prognostic predictor of CMV disease (Martin-Gandul
et al., 2013). However, measuring the viral load in specific
compartments such as tissues and body fluids may be an
alternative way to differentiate between latent infection
and reactivation, as well as to assess disease activity in sit-
uations where the plasma viral load correlates poorly with
disease activity (Kouri et al. 2010; Petrisli et al., 2010). The
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with regard to the onset of CMV viremia, together with
the fact that a cutoff value of CMV viral load >219 copies/
mL in urine is associated with the subsequent detection of
CMV in plasma, is an important issue to consider for
tracking Cuban transplant patients and indicates the pos-
sibility of using quantitative monitoring of CMV in urine,
besides plasma, as a diagnostic tool for the early predic-
tion of patients who may develop viremia.
The exact cut-off value of CMV viremia for initiation of
preemptive treatment has not yet been defined (dela
Torre-Cisneros et al., 2011). In randomized trials in SOT
this cut-off has been set at 300000 copies/mL (Gerna
et al., 2007). Furthermore, the quantification of virus in
urine samples of kidney transplants recipients has proven
to be reliable in providing clinically relevant information,
particularly for BKV management, where no specific anti-
viral therapy is currently available and the reduction of the
immunosuppressive regimen depends on the viral loads
level in urine and plasma specimens (Mischitelli et al.,
2008). Thus, in agreement with recent reports (Farfan
et al., 2011), the present study reinforces the urgent need
of inclusion of qRT-PCR methods for the management of
viral infections in the Cuban transplantation program.
The longitudinal analysis of the virus loads monitored
during the 34 weeks revealed that, at the time of trans-
plantation (time 0), asymptomatic excretion of several
viruses was observed, indicating that the lack of antiviral
prophylaxis could jeopardize the success of graft take.
Generally, the occurrence of viral DNAemia is determined
by the capacity of the immune system to control viral
replication. Consistently, the majority of the studied cases
with viral DNAemia were detected within the first 100 days
post transplantation. CMV replication increased between
weeks 10–14 after transplantation, probably due to the
discontinuation of antiviral prophylaxis along with the
immunosuppression regimen (Razonable, 2013). BKV,
although less frequent, was detected in 35.3% of patients
and remained detectable during the follow-up. To date, no
specific antiviral treatment has proven to be effective, and
the only intervention of choice is reduction and/or switch-
ing of immunosuppressive drugs (Suwelack et al. 2012).
As expected, CMV was the major cause of morbidity in
the present study, although ADV caused disease in one
patient. CMV is recognized as the major infectious compli-
cation in transplant recipients producing a variety of end-
organ diseases or CMV syndrome with fever and leucopenia
(Cordero et al., 2012; de la Torre-Cisneros et al., 2011). In
addition to directly attributable morbidity, CMV has indir-
ect effects (Caston Osorio and Zurbano Goni 2011), includ-
ing an immunomodulating activity that is likely responsible
for an increased risk of additional opportunistic infections.
One kidney recipient developed an ADV-associated fe-
brile disease, which has been previously described; however,this virus may also produce hemorrhagic cystitis colitis,
hepatitis, pneumonitis and encephalitis (Lynch et al., 2011).
BKV infection is associated with BKV-associated nephropa-
thy or hemorrhagic cystitis that affects up to 10% of bone
marrow- and kidney-transplant patients; however, none of
the studied patients developed such a type of complication
(Rinaldo and Hirsch, 2007).
Seven patients under specific antiviral therapy (Table 3)
were accurately evaluated with regard to the response to
the antiviral therapy, confirming that the use of qRT-
PCR is critically important for the management of the
transplanted patients, as has been described in most of
the current international guidelines (Le Page et al., 2013;
Tong et al., 2011). Yet, preemptive GCV therapy limited
the extent of viral DNAemia and the manifestation of
viral disease such that no death from viral DNAemia or
disease associated to viral activation occurred in our co-
hort. We opted for a combination of prophylactic GCV
and ACV administration and preemptive GCV therapy.
Conclusions
We have reported our results on a prospective and com-
prehensive quantitative PCR-guided viral monitoring pro-
gram, for simultaneous detection of nine different viruses.
Even though the sample size was small, this represented
the entire population of Cuban pediatric solid organ trans-
plant recipients during the study period.
Some observed information during the viral monitoring
ads new or confirms known information worldwide. How-
ever, this is the first study using qRT-PCR for the follow-
up of transplanted patients in Cuba.
The results presented herein indicate that many patients
develop active viral infections following transplantation.
Some patients showed active infection by more than one
virus either infected sequentially or concurrently. CMV
was the most frequent virus detected in any sample during
the follow up and mainly caused clinical symptoms, al-
though the levels of viral load were not correlated with
symptoms. This viral monitoring in combination with
early initiation of preemptive GCV or VGV should effect-
ively prevent the development of critical viral disease,
thus, the implementation of quantitative viral load meas-
urement for routine monitoring could be the best strategy




The study population included all Cuban pediatric pa-
tients who underwent SOT between November 2009 and
December 2012. A total of 34 consecutive pediatric
patients undergoing SOT (23 liver and 11 kidney) at the
liver and kidney transplant units for pediatric patients in
Cuba (University Pediatric Hospital “William Soler” and
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studied prospectively for a period of 34 weeks, using qRT-
PCR for detection of 9 different viruses. Table 1 provides
general information about our cohort.
This research has been approved by the Ethical Commit-
tees of the participating institutions, and complies with the
principles laid down in the Declaration of Helsinki. Parents
provided informed consent with regard to the transplant-
ation procedure, including extended viral monitoring. Clin-
ical and therapeutic data from the transplanted patients
were collected through a questionnaire performed by the
parents as well as from clinical records of the patients.
Immunosuppressive and prophylactic antiviral therapy
was based on the guidelines of the respective study proto-
cols of the Protocolo de Trasplante Hepático en Pediatría,
2005, University Pediatric Hospital “William Soler” and
Protocolo de Trasplante renal, 1988, University Pediatric
Hospital of “Centro Habana”) (Table 1).
Briefly, immunosuppression for SOT was initiated
4 hours before transplantation and consisted of induction
therapy with cyclosporine (Cs) (dosage 8–10 mg/kg/day
and adjusted according to the creatinine level and cyclos-
porinemia level). Mycophenolate mofetil (MMF) was
initiated on day 3 at a dosage of 600–1200 mg/m2 for
3 months or tacrolimus (dosage 0.1-0.3 mg/kg/day). In
addition, 7 kidney and 3 liver recipients were also treated
with basiliximab (dosage in ≤30 kg 10 mg and ≥30 kg
20 mg, at day 0 and 4 after the graft) or thimogam (dosage
15 mg/kg/day/14 days). Methylprednisolone (dosage, 10–
15 mg/kg) was administered for both types of transplant
recipients on the day of transplant that was reduced weekly
from 2 mg/kg mg/day until 0.5 mg/kg/day, during the first
month following transplantation. At the 2nd and 3rd month
0.25 mg/kg/day were used, and thereafter the dosage was
administered every 48 hours.
Recommended levels of cyclosporinemia, for kidney re-
cipients: C0 (1
st month: 250–350 ng/mL, 2nd -3rd month:
200–300 ng/mL, 4th-12th months: 150–200 ng/mL, after
the 1st year: 100–200 ng/mL) and C2 (1
st month: 1150–
1550 ng/mL, 2nd -3rd month: 800–1200 ng/mL, 4th-6h
month: 750–900 ng/mL and after the 6th month: up to
650 ng/mL).
Recommended levels of cyclosporinemia, for liver re-
cipients: 1st two weeks: 250–350 ng/mL, 3rd week-3rd
month: 200–300 ng/mL, 4th-12th months: 150–200 ng/
mL, afterwards: 100–150 ng/mL).
Recommended levels of tacrolimus (only used for live
donor’s recipients): 0 - 2nd weeks: 10–20 ng/mL, 3rd –
4th weeks: 10 – 15 ng/mL, 2nd – 3rd weeks: 5–15 ng/
mL and afterwards: 5–10 ng/mL.
VGC (520 mg/m2 every 12 hours) or GCV (5 mg/kg
every 12 hours) was administered as prophylaxis for 1 to
3 months for both type of recipients and evaluated ac-
cording to creatinine levels as well as platelets andleucocytes counts. Additionally, Aciclovir (ACV) was ad-
ministered for two months following GCV or VGV prop
hylaxis in liver transplanted patients (Table 1). Preemp-
tive therapy with GCV or VGV (at prophylactic doses)
was used for the treatment of CMV infections before the
appearance of clinical symptoms and after viremia detec-
tion or the increase of viral excretion. The decision of
initiation antiviral therapy was made by the attending
physician.
Whenever an infectious complication (bacterial, fungal
or viral) was detected, the specific treatment was admin-
istered according to the guidelines described above. Viral
disease was defined according to previously published
guidelines (Ljungman et al., 2002).
Collection of samples
One milliliter of plasma and urine samples was obtained
weekly in the first month post-transplant. At thirty to
90 days post-transplantation, samples were collected every
two weeks. After 90 days, samples were collected monthly
up to 34 weeks (238 days) post-transplant.
Viral monitoring using the real-time technique
Viral monitoring was performed at the STI Laboratory of
the Institute of Tropical Medicine ¨Pedro Kouri¨ (IPK,
Havana, Cuba) since it is the only center currently per-
forming molecular diagnosis of viral infections, thus sam-
ples from all patients were sent to IPK for testing. Viral
detection and quantification of CMV, EBV, HSV type 1
and 2 (HSV1 and HSV2), VZV, HHV6, ADV, and polyo-
maviruses (BKV and JCV) was prospectively monitored in
plasma and urine samples by real-time hybridization as-
says for 34 weeks after transplantation.
DNA extraction was performed from plasma and urine
using QIAmp DNA minikit (Qiagen, Germany) following
the recommendations of the manufacturers. Seven differ-
ent qRT-PCR kits were used for the detection and quanti-
fication of CMV, EBV, HSV (including HSV1 and HSV2
subtyping), HHV6, VZV, polyomaviruses (BKV and JCV
within the same kit), and ADV, following the protocols
and the cycling parameters described by the manufac-
turers (TIB MOLBIOL, Germany). These kits were
designed to be assayed under the LightCycler 1.5 platform
(Roche Diagnostics, Germany). They include the mix
(Light Mix) of specific primers and probes (hybridization
probes) for each specific virus and the viral standards
(positive DNA controls) ranging from 10 to 106 copies/μL
which allow to construct the standard curve and quantify
the viral DNA load in each patient’s sample; in addition
the kits also include an internal control.
The qRT-PCR mix for each assay was prepared using
Light Mix 2–4 uL (specific for each virus), 2-4uL of Light-
Cycler FastStart DNA Master HybProbe (depending on
the specific protocol for each virus) (Roche, Germany),
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25 mM MgCl, and 5uL of the extracted DNA from each
sample. The analysis and quantification of the samples
were automatically performed by the second derivative
maximum method, version 3.3 of the LightCycler software.
The results were converted to copies/mL according to the
formula (Result in copies/mL = Result in copies/μL × Elu-
tion volume in μL/ Sample volume in mL). Clinical sam-
ples were considered negative (non detectable viral load) if
the crossing point exceeded the cycle 40 or if the viral load
was below 10 copies/mL, described as the analytical detec-
tion limit of the kits.
Statistical analysis
For statistical analysis, a database was created using the
package SPSS version 17.0. In order to determine an asso-
ciation among clinical features, serological results and/or
virological findings, the odds ratio (OR) with 95% of confi-
dence intervals were calculated. The presence of statisti-
cally significant association (p), was considered if p ≤ 0.05.
Comparisons between different groups of patients or be-
tween samples were made by using the Fisher exact test,
for categorical data, and for numerical variables the
Kruskall-Wallis and Mann–Whitney tests were used.
Quantitative RT-PCR was analyzed in two ways. The de-
tection of any virus in patients/samples was interpreted as
qualitative outcome: considering positive all patients or
samples with more than 10 copies/mL and negative, below
this number. However, with regard to the analysis of the
viral load distribution in patients/samples, the results were
interpreted as quantitative outcome and the numerical
values of the viral load in each clinical sample were
considered.
We assessed the discriminative power of the viral load
level using recipients-operating characteristic curves
(ROC). Their accuracy to discriminate between the viral
load of a virus associated with further detection of another
virus and/or the assessment of the cutoff viral load in a
fluid associated with subsequent excretion of the same
virus in the other fluid was classified according to the value
of the area under ROC curve (15) in: non-informative
(AUC_0.5), less accurate (0.5 < AUC_0.7), moderately ac-
curate (0.7 < AUC_0.9), highly accurate (0.9 < AUC < 1)
and perfect (AUC= 1). The value of the viral load with the
highest sensitivity, above 50% specificity, for discriminating
the detection of other virus was taken as the optimal cut-
off point.
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